Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis.
CONCLUSIONS: Tocilizumab therapy for 2 years significantly and clinically decreased fatigue. BMD remained stable and no new safety issue was reported.
PMID: 29629732 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
More News: Actemra | Arthritis | Chronic Fatigue Syndrome | General Medicine | Israel Health | Middle East Health | Orthopaedics | Osteoporosis | Rheumatoid Arthritis | Rheumatology | Statistics | Study | Women